A citation-based method for searching scientific literature

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
Times Cited: 104



Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes.
Nitesh D Kuhadiya, Husam Ghanim, Aditya Mehta, Manisha Garg, Salman Khan, Jeanne Hejna, Barrett Torre, Antoine Makdissi, Ajay Chaudhuri, Manav Batra, Paresh Dandona. J Clin Endocrinol Metab 2016
Times Cited: 44




List of shared articles



Times cited

Double Diabetes: A Growing Problem Requiring Solutions.
Djordje S Popovic, Nikolaos Papanas. Exp Clin Endocrinol Diabetes 2022
0

Quantifying the relationship between dapagliflozin and loss of weight in type 1 diabetes mellitus patients.
Dong-Dong Wang, Su-Mei He, Yan Han, Tian-Yun Wang, You-Mei Wang. J Clin Pharm Ther 2022
0

Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis.
Siddhartha Dutta, Tarun Kumar, Surjit Singh, Sneha Ambwani, Jaykaran Charan, Shoban B Varthya. J Family Med Prim Care 2022
0

The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis.
Saniya Tandon, Salma Ayis, David Hopkins, Seeromanie Harding, Marietta Stadler. Diabetes Obes Metab 2021
4

Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations on the use of sodium-glucose cotransporter inhibitors with insulin for treatment of type 1 diabetes (Updated October 2020).
Umesh Dashora, Dipesh C Patel, Robert Gregory, Peter Winocour, Ketan Dhatariya, Susannah Rowles, Andrew Macklin, Gerry Rayman, Dinesh Nagi. Diabet Med 2021
3

Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: A meta-analysis of randomized controlled trials.
Hailan Zou, Lili Liu, Jia Guo, Hongjuan Wang, Siyun Liu, Yixuan Xing, Chao Deng, Yang Xiao, Zhiguang Zhou. J Diabetes Investig 2021
2

A systematic review and dose-response meta-analysis on the efficacy of dapagliflozin in patients with type 1 diabetes mellitus.
Ahmed Abu-Zaid, Abdulaziz Khalaf Altowairqi, Thusharika Dissanayaka, Artem Oganesyan, Akshaya Srikanth Bhagavathul, Habeeb Alhabeeb, Amirah Baradhwan, Sara Alomar, Sebastian Tom. Pharmacol Res 2021
1

Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta-analysis of randomized controlled trials.
Yuxin Huang, Zeju Jiang, Yiping Wei. Exp Ther Med 2021
2

The efficacy of dapagliflozin for type 1 diabetes: a meta-analysis of randomized controlled studies.
Jian Ma, Yanhong Zhao, Huihui Fan, Jia Liu. Afr Health Sci 2021
1

Evaluation of the safety of sodium-glucose co-transporter-2 inhibitors for treating patients with type 1 diabetes.
Weihao Wang, Lina Zhang, Xiaobei Pei, Qi Pan, Lixin Guo. Diabetes Obes Metab 2020
3

Adjunct therapies in treatment of type 1 diabetes.
Itivrita Goyal, Alamgir Sattar, Megan Johnson, Paresh Dandona. J Diabetes 2020
7

Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
Giovanni Musso, Antonio Sircana, Francesca Saba, Maurizio Cassader, Roberto Gambino. PLoS Med 2020
9

Sodium-glucose cotransporter 2 inhibitor-associated diabetic ketoacidosis in patients with type 1 diabetes: Metabolic imbalance as an underlying mechanism.
Wataru Ogawa, Yushi Hirota. J Diabetes Investig 2019
4

Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
Schafer Boeder, Steven V Edelman. Diabetes Obes Metab 2019
21


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy